Home /Biblio

Biblio

Found 399 results
Author Keyword Title Type [ Year(Asc)]
2014
F. Collinson, Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M. K. B., Ledermann, J. A., Colombo, N., and Swart, A. Marie, “Optimal treatment of early-stage ovarian cancer.”, Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.
M. R. Stockler, Hilpert, F., Friedlander, M. Leonard, King, M. Trudy, Wenzel, L. B., Lee, C. Khoon, Joly, F., de Gregorio, N., Arranz, J. Angel, Mirza, M. Raza, Sorio, R., Freudensprung, U., Sneller, V., Hales, G., and Pujade-Lauraine, E., “Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.”, J Clin Oncol, vol. 32, no. 13, p. 1316, 2014.
T. Sugiyama, Fujiwara, K., Ohashi, Y., Yokota, H., Hatae, M., Ohno, T., Nagai, Y., Mitsuhashi, N., Ochiai, K., and Noda, K., “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.”, Ann Oncol, vol. 25, no. 5, pp. 1011-7, 2014.
M. Okadome, Saito, T., Tanaka, H., Nogawa, T., Furuta, R., Watanabe, K., Kita, T., Yamamoto, K., Mikami, M., Takizawa, K., and Group, J. Gynecologi, “Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2”, J Obstet Gynaecol Res, vol. 40, pp. 561-9, 2014.
K. Harano, Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., and Sugiyama, T., “Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: JGOG Trial (JGOG3016).”, Ann Oncol, vol. 25, no. 1, pp. 251-7, 2014.
R. M. Glasspool, Brown, R., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., Gabra, H., Halford, S. E., Walker, J. L., Appleton, K., Ullah, R., Kaye, S. B., and Group, S. Gynaecolog, “A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer”, Br J Cancer, vol. 110, pp. 1923-9, 2014.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., “Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study.”, J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, “Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group”, Int J Gynecol Cancer, 2014.
M. Leonard Friedlander, Stockler, M., O'Connell, R., Voysey, M., Oza, A. M., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K. Marie, Butow, P., King, M. Trudy, and Group, S. Benefit St, “Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup symptom benefit study”, Int J Gynecol Cancer, vol. 24, pp. 857-64, 2014.
G. Mangili, Lorusso, D., Brown, J., Pfisterer, J., Massuger, L., Vaughan, M., Ngan, H. Y. S., Golfier, F., Sekharan, P. K., Charry, R. Cortés, Poveda, A. M., Kim, J. - W., Xiang, Y., Berkowtiz, R., and Seckl, M. J., “Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S109-16, 2014.
D. Trudel, Desmeules, P., Turcotte, S., Plante, M., Gregoire, J., Renaud, M. C., Orain, M., Bairati, I., and Tetu, B., “Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis”, Mod Pathol, 2014.
2013
D. Shaw, Clamp, A. R., and Jayson, G. C., “Angiogenesis as a target for the treatment of ovarian cancer”, Curr Opin Oncol, vol. 25, pp. 558-65, 2013.
G. Emile, Chauvenet, L., Tigaud, J. M., Chidiac, J., E. Lauraine, P., and Alexandre, J., “A clinical experience of single agent bevacizumab in relapsing ovarian cancer”, Gynecol Oncol, vol. 129, pp. 459-62, 2013.
M. Mikami, Aoki, Y., Sakamoto, M., Shimada, M., Takeshima, N., Fujiwara, H., Matsumoto, T., Kita, T., Takizawa, K., Cervical, D. Committee, and Group, V. Cancer Jap, “Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group”, Int J Gynecol Cancer, vol. 23, pp. 1655-60; quiz 1661-2, 2013.
K. Ushijima, Kamura, T., Tamura, K., Kuzuya, K., Sugiyama, T., Noda, K., and Ochiai, K., “Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.”, Int J Clin Oncol, vol. 18, no. 1, pp. 126-31, 2013.
J. Ang, Gourley, C., Powell, C., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T. A., Sandhu, S., Banerjee, S., Chen, L., Friedlander, M. Leonard, Kaufman, B., Oza, A. M., Matulonis, U., Barber, L., Kozarewa, I., Fenwick, K., Assiotis, I., Campbell, J., Chen, L., de Bono, J., Gore, M. E., Lord, C., Ashworth, A., and Kaye, S. B., “Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study”, Clin Cancer Res, vol. 19, pp. 5485-93, 2013.
G. A. Martin, Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., Garcia, Y., Lopez-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., and A. Velasco, P., “GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012”, Clin Transl Oncol, vol. 15, pp. 509-25, 2013.
C. L. Creutzberg, Kitchener, H. C., Birrer, M. J., Landoni, F., Lu, K. H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P. J., Quinn, M., Salvesen, H. B., Thomas, G., and Meeting, G. C. I. G. Endometria, “Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era”, Int J Gynecol Cancer, vol. 23, pp. 1528-34, 2013.
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., “Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.”, Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
B. J. Monk, Pujade-Lauraine, E., and Burger, R. A., “Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.”, Ann Oncol, vol. 24 Suppl 10, p. x58, 2013.
N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, “Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial”, Lancet Oncol, vol. 14, pp. 1020-6, 2013.
S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., “A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.”, Ann Oncol, vol. 24, no. 3, p. 687, 2013.
D. Handolias, Quinn, M., Foo, S., Mileshkin, L. R., Grant, P., Dutu, G., and Rischin, D., “Oral cyclophosphamide in recurrent ovarian cancer”, Asia Pac J Clin Oncol, 2013.
K. D. Steffensen, Waldstrom, M., Pallisgard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., and Jakobsen, A., “Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study”, Int J Gynecol Cancer, vol. 23, pp. 73-80, 2013.
J. F. Liu, Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., Ivy, P., and Matulonis, U. A., “A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer”, Eur J Cancer, vol. 49, pp. 2972-8, 2013.

Pages